Beppe Severgnini, one of the most influential journalists in Italy, talks to ProMarket about what the U.S. can learn from Italy on how to defeat populist plutocrats.
Read more
Study: Politically-Connected Firms More Likely to Receive Favorable Merger Reviews from Antitrust Regulators
A new study finds that firms connected to members of the House and Senate judiciary committees are more likely to receive favorable merger reviews.
Read more
Raghuram Rajan: Populist Nationalism Is “the First Step Toward Crony Capitalism”
The former governor of the Reserve Bank of India discussed the “concentrated and devastating” impact that technology and trade had on blue-collar communities, the anger toward “totally discredited” elites following the 2008 financial crisis, and the subsequent rise of populist nationalism during a keynote address at the Stigler Center’s conference on the political economy of finance.
Read more
Bribery, Cooperation, and the Evolution of Prosocial Institutions
How the science of cooperation and cultural evolution will give us new tools in combating corruption.
Read more
The Berlusconi Voter, Taken Seriously: a Little Exercise in Historical Comprehension
The Berlusconi phenomenon in Italy both anticipated and exhibits features that epitomize the plight of Western politics.
Read more
Eliot Spitzer: The Democratic Party Has Become the Party of the Status Quo
Former New York governor Eliot Spitzer talks about antitrust, digital platforms, economic concentration, and regulatory capture. Part 2 of 2.
Read more
The Big Picture: Clientelism, Plutocracy, and Democratization
Why is the electoral process not enough to rid nations of pathological political distortions such as cronyism and corruption?
Read more
Eliot Spitzer: The U.S. Never Had the Will and the Ability to Hold the Most Powerful to Account
In a special interview with ProMarket, former New York governor Eliot Spitzer talks about financial regulation, regulatory capture, and antitrust. Part 1 of 2.
Read more
How Biology Explains Back-Scratching Between Wall Street and Government
The revolving door of government and business explained in the lab.
Read more
Where Friedman Was Wrong
A new paper by Oliver Hart and Luigi Zingales argues that a company’s objective should be the maximization of shareholders’ welfare, not value.
Read more
“The Pharmaceutical Industry Has a Large Amount of Control Over the Field of Oncology”
In the second part of our two-part interview with Daniel Goldstein, MD, an oncologist who studies the influence of business interests on healthcare, we talk about the capture of the health system by pharmaceutical companies.
Read more
When Medical Experiments Serve the Business Needs of Pharmaceutical Firms Instead of Science
The first part of a two-part interview with Daniel Goldstein, MD, an oncologist who also studies the influence of business interests on healthcare—from treating patients to conducting drug trials to holding health-related events. In the first part of this interview, we talk about capitalism and healthcare, what motivates physicians, and the effectiveness of healthcare systems in the U.S., the U.K., and Israel.
Read more